About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline
LOG IN
LOG IN

1 Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid 1 (March 2019)

handle is hein.congrec/cbopspen0001 and id is 1 raw text is: m MARCH 2019 Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid Summary In recent years, the prices charged for certain types of drugs-referred to as specialty drugs-have become a source of concern for many policymakers. Such drugs typically treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or patient monitoring. From 2010 through 2015, specialty drugs accounted for a growing share of new drugs introduced to the market, and they were introduced at much higher prices than nonspecialty drugs. Those factors have contributed to increased spending on prescription drugs in Medicare Part D (Medicare's prescription drug benefit) and Medicaid. Counting spending by all parties: * Net spending on specialty drugs in Medicare Part D rose from $8.7 billion in 2010 to $32.8 billion in 2015. * Net spending on specialty drugs in Medicaid roughly doubled from 2010 to 2015, rising from $4.8 billion to $9.9 billion. In 2015, brand-name specialty drugs accounted for about 30 percent of net spending on prescription drugs under Medicare Part D and Medicaid, but they accounted for only about 1 percent of all prescriptions dispensed in each program. Because Medicare Part D and Medicaid are two large purchasers of prescription drugs, increases in spending for those drugs could have important implications for the federal budget. In this report, the Congressional Budget Office examines the net prices paid for specialty drugs and spending on those drugs in Medicare Part D and Medicaid over the 2010-2015 period. (In each program, the net price for many drugs is lower than the amount paid to pharma- cies, also referred to as the retail price, because of man- ufacturers' rebates and other discounts.) Key findings include the following: The net prices paid for brand-name specialty drugs are much higher in Medicare Part D than in Medicaid. In 2015, the weighted average net price for 50 top-selling brand-name specialty drugs in Medicare Part D was $3,600 per standardized prescription-a measure that roughly corresponds to a 30-day supply of medication-whereas the weighted average net price for the same set of drugs in Medicaid was $1,920. That difference was attributable to much larger rebates in Medicaid than in Medicare Part D. * Specialty drugs accounted for a growing share of total net drug spending from 2010 to 2015 in both pro- grams, rising from 13 percent to 31 percent of such spending in Medicare Part D and from 25 percent to 35 percent in Medicaid. * For beneficiaries in the Medicare Part D program who took brand-name specialty drugs, average annual net spending on such drugs per person (in 2015 dollars) roughly tripled over the 2010-2015 period- from $11,330 in 2010 to $33,460 in 2015. 1. For a deeper examination of this topic and a more detailed discussion of the methods used in CBO's analysis, see Anna Anderson-Cook, Jared Maeda, and Lyle Nelson, Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid An In-Depth Analysis, Working Paper 2019-02 (Congressional Budget Office, March 2019), www.cbo.gov/publication/55011.

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Purchase Access

Contact us for annual subscription options:

Contact Us

Already a HeinOnline Subscriber?

Log In

profiles profiles most